Pieris Pharmaceuticals (NASDAQ:PIRS) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Separately, HC Wainwright set a $9.00 price target on shares of Pieris Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, October 18th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Pieris Pharmaceuticals currently has an average rating of “Buy” and an average price target of $9.00.

Shares of Pieris Pharmaceuticals (PIRS) opened at $6.07 on Friday. Pieris Pharmaceuticals has a twelve month low of $1.34 and a twelve month high of $6.65.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.05. The business had revenue of $3.93 million during the quarter, compared to analysts’ expectations of $1.52 million. Pieris Pharmaceuticals had a negative net margin of 321.83% and a negative return on equity of 221.93%. The firm’s revenue was up 400.3% compared to the same quarter last year. research analysts anticipate that Pieris Pharmaceuticals will post -0.72 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC acquired a new position in shares of Pieris Pharmaceuticals during the first quarter valued at about $661,000. Sphera Funds Management LTD. grew its holdings in shares of Pieris Pharmaceuticals by 10.0% during the second quarter. Sphera Funds Management LTD. now owns 1,100,000 shares of the biotechnology company’s stock valued at $5,566,000 after buying an additional 100,000 shares during the last quarter. Teachers Advisors LLC acquired a new position in shares of Pieris Pharmaceuticals during the second quarter valued at about $308,000. First Quadrant L P CA acquired a new position in shares of Pieris Pharmaceuticals during the third quarter valued at about $473,000. Finally, Schwab Charles Investment Management Inc. acquired a new position in shares of Pieris Pharmaceuticals during the second quarter valued at about $292,000. Hedge funds and other institutional investors own 50.45% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “ValuEngine Lowers Pieris Pharmaceuticals (PIRS) to Sell” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/valuengine-lowers-pieris-pharmaceuticals-pirs-to-sell/1738267.html.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.